Interestingly, the results didn’t provide valid evidence to demonstrate the casual relationship between IL-13 and developmental risk of IL-13 that blocking IL-13 alone seemed not to achieve sufficient lung function benefits in patients with IPF. The gene discussed is IL13; the disease is idiopathic pulmonary fibrosis.